The analysis of minimal residual disease (MRD) has assumed a growing role in the follow-up of patients with acute lymphoblastic leukemia (ALL). We have applied multiparameter flow cytometry (FC) with 'live-gate' analysis and allele-specific oligonucleotide ( 
Introduction
The monitoring of minimal residual disease (MRD) has assumed a constantly growing role in the clinical management of patients with acute lymphoblastic leukemia (ALL). [1] [2] [3] The persistence of high levels of MRD is associated with poor outcome and generally predicts clinical relapse. [4] [5] [6] [7] [8] [9] A unique pattern of junctional regions of rearranged immunoglobulin heavy chain (IgH) and T cell receptor (TcR) genes has been widely applied as leukemia-or patient-specific targets for Southern blot or polymerase chain reaction (PCR)-based MRD analysis (reviewed in Refs 1, 3) . The sequences of junctional regions have been determined at diagnosis and sequence-specific oligonucleotides have been designed for further use as patient-specific primers. 10 However, due to high sensitivity, gene rearrangements in normal lymphocytes can also be amplified by PCR method. Heteroduplex analysis of PCR-amplified junctional regions of IgH and TcR genes has recently been found to be highly concordant with the Southern blot method (previously considered as the 'golden standard' for this analysis), offering a less laborious, non-radioactive alternative for the detection of clonal lymphoid cell populations. 11 Further progress has been made by the application of quantitative PCR methods that make possible a more accurate determination of leukemic cell frequency in the bone marrow (BM). [12] [13] [14] Recently, extensive work has focused on characterization of B and T cell phenotypes present in normal BM, and on definition of the phenotypic differences between these cells and ALL blasts. [15] [16] [17] [18] [19] [20] [21] [22] This knowledge, together with the application of the sensitive 'live gate' analysis has improved the specificity and sensitivity of MRD detection by flow cytometry. 2, 23 However, studies using both the PCR-based and immunophenotype-based methods of MRD detection in the same patient population are scarce. [24] [25] [26] The aim of the present study was to compare two methods of MRD detection: flow cytometry (FC) and allele-specific oligonucleotide (ASO)-PCR for TcR. The latter method was chosen due to the high representation of T-ALL cases in the available material. However, the TcR␥ and/or ␦ rearrangements have also been demonstrated in 80% of childhood B-precursor ALL. 27 The methods were applied in the same follow-up samples from ALL patients, which allowed comparison of their sensitivity. The possibility of comparing the prognostic significance of the two methods was limited since the study was performed on selected material. The methodology employed in the study was consistent with methods agreed upon within the BIOMED I Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. 6, 19, 21 
Materials and methods

Patients
A total of 181 BM samples (30 from diagnosis and 151 from follow-up) from 30 patients (28 children and 2 adults, M:F = 13:17) with ALL were studied. The morphological diagnosis of ALL was established based on microscopic investigation of May-Grü nwald-Giemsa stained BM smears. The immunologic diagnosis and classification of ALL was made according to well-established criteria. 28 There were 10 patients with T-ALL and 20 with B-precursor ALL (Table 1) . Nine patients were considered as standard risk (SR), seven patients as intermediate risk (IR) and 14 patients as high-risk (HR). 29 One patient (No. 19) was followed after relapse of the disease. There was no active selection of patients. However, there was more often material available from patients with T cell ALL and from patients with high white blood cell counts at diagnosis, resulting in a relatively high representation of HR group patients.
The children were treated according to the Nordic Society of Pediatric Hematology and Oncology 1992 (NOPHO-92) protocols. 29 The adults were treated with intravenous cyclophosphamide, vincristin, daunorubicin, cytosine arabinoside, steroids and intrathecal methotrexate. Results of MRD studies did not influence clinical decisions concerning treatment of the patients. Two patients (Nos 17 and 22) underwent bone marrow transplantation (BMT) after induction therapy, due to high-risk criteria (mediastinal involvement and t(9;22), respectively). Another patient (No. 19) was transplanted after the second relapse of disease. This study was approved by the Ethics Committee at Karolinska Hospital.
Bone marrow samples
BM cell suspensions were collected in heparin immediately diluted 1/1 (v/v) in sterile physiological saline and maintained at room temperature (RT) until processed. Flow cytometry was performed within 24 h. For molecular analysis, cells from BM were separated by Ficoll-Isopaque (Pharmacia Amersham, Uppsala, Sweden) gradient centrifugation, washed twice, re-suspended in PBS supplemented with 50% human AB serum and 10% DMSO, and frozen in liquid nitrogen. Samples with low numbers of cells were separated from plasma by centrifugation. Pellets were frozen and stored at −80°C until use.
PCR amplifications
Isolation of genomic DNA was performed using standard techniques (WIZARD Genomic DNA Purification Kit; Promega, Madison, WI, USA).
The clonal sequence of the TcR␥ and TcR␦ rearrangements present in BM samples collected at diagnosis was determined by using primers developed and approved by the BIOMED 1
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Concerted Action (Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation).
One g DNA aliquots were added to PCR using consensus oligonucleotides V␥I-J␥1.3/2.3, V␥II-J␥1.3/2.3, V␥IV-J␥1.1/2.1, V␦2-D␦3 and D␦2-D␦3 family-specific primers. 10 These primers have been shown to detect 97% of TcR␥ and 80% of TcR␦ gene rearrangements in B-precursor ALL, respectively. 27 The PCR reaction was carried out essentially as described by Saiki et al. 30 The reaction was performed in 100 l volume containing 1× reaction buffer (RB: Tris-HCl 50 mM pH 8.3, KCl 50 mM and 1.5 mm MgCl 2 ), 30 pmol of each primer, 200 M dNTP, 2 U Gold TaqPolymerase (Perkin Elmer (PE Bio) Biosystems, Foster City, CA, USA). PCR was performed in a PE Bio GeneAmp PCR system 9600 for 35 cycles. After an initial step at 94°C for 10 min, denaturing was performed at 95°C for 45 s annealing at 60°C for 90 s and extension at 72°C for 90 s. The final extension time was 7 min at 72°C. The amplification product was analyzed by gel electrophoresis (1.5% agarose gel (Pharmacia Amersham) and stained by 0.5 mg/ml ethidium bromide (Bio-Rad Laboratories, Hercules, CA, USA).
V␥-J␥ homo-heteroduplex analysis
V␥-J␥ homo-heteroduplex analysis was performed as described by Bottaro et al. 31 Fifteen l of each PCR product was mixed with 5 l Dye I (sucrose) and heated at 94°C for 5 min., then rapidly cooled to 50°C and incubated for 1 h. The samples were loaded on 11% non-denaturing polyacrylamide gel (PAGE, 29:1 acrylamide/bis; (Bio-Rad Laboratories) in 1 × TBE and separated at 11 mA at 4°C for 20 h. The gel was then stained with ethidium bromide. Cases showing homo-or heteroduplex pattern 32 identified by PAGE were cloned and sequenced (see below).
Cloning and sequencing
PCR products obtained with consensus primers were cloned using TA Cloning Kit (Invitrogen, Carlsbad, CA, USA). Cloned products were directly sequenced with consensus sequencing primers using the Sequenase Ver.2.0 kit (Pharmacia Amersham, Cleveland, OH, USA). From each patient, seven or more identical clones were sequenced to define the leukemic clone. The specific VNJ region segments present in each individual clone (Table 2) were determined by comparison with the germline sequence. Allele-specific oligonucleotides (ASO) were designed for each patient (Table 3) using OLIGO TM 5.0 primer analysis software (Dr W Rychlik, National Bioscience Inc., Plymouth, MN, USA).
Detection of MRD by allele-specific oligonucleotides (ASO)-PCR
Nested ASO-PCR was performed as described by Seriu et al. 14 Briefly, serial dilutions (starting from 1 g undiluted DNA) of Leukemia diagnostic BM samples in DNA from peripheral blood leukocytes of healthy donors were amplified using consensus primers (see above). DNA samples from remission BM were amplified in parallel. One l of the first PCR product was diluted in water (1:99) to minimize the non-specific amplification of polyclonal DNA. Two l of the diluted first PCR product were used as a template for allele-specific amplification in the second round PCR (ASO-PCR). The reaction was performed in 50 l volume containing 1 × RB, 50 M TMAC, 200 M dNTP, 2 U Gold TaqPolymerase (PE Biol), 15 pmol of allele-specific primer and V␥ or V␦ inner primer (Table 3) . PCR reactions were carried out in the PE Bio GeneAmp 9600 system for 25 to 35 cycles. The number of cycles was optimized for each ASO primer to obtain the maximal amplification of the leukemic DNA and avoid the non-specific amplification of polyclonal control DNA. As a control DNA from peripheral blood leukocytes of healthy donors was used.
After an initial step at 94°C for 10 min, denaturing was performed at 94°C for 45 s. Annealing temperature depended on ASO primer (90 s). Extension was performed at 72°C for 90 s and the reaction was completed with the final extension at 72°C for 7 min. The PCR products were separated in 1% agarose +2% NuSieve gel (FMC Bio Products, Rockland, ME, USA) and stained with ethidium bromide (Figure 1) .
The sensitivity level for each individual patient was determined by serial dilutions of the diagnosis sample in pooled peripheral blood leukocyte DNA. The levels are given in Table 3 and exemplified in Figure 1 . The results for each patient follow-up were evaluated semi-quantitatively by comparison with the serial dilution experiments run in parallel. It was not possible to determine the actual concentration of leukemic cells in samples with positive results. In samples with negative PCR results the MRD level (eg Ͻ0.001%, Ͻ0.01%, Ͻ0.1%) was determined by the level of detection.
Additionally, in five samples from four patients with discrepant results between FC and PCR (see Results) the possibility of the presence of factors inhibiting PCR was investigated by mixing of 100 ng patient DNA with 900 ng of control DNA and amplifying with consensus primers. The PCR products were run on agarose gel and the bands from samples containing patient DNA were compared visually with control samples.
Flow cytometry (FC)
At diagnosis, leukemic blasts were immunophenotyped by multiparameter FC with triple immunofluorescence using monoclonal antibodies (MAb) conjugated with fluorescein (FITC), phycoerythrin (PE) and PE-cyanine 5 (PECy5) or peridin chlorophyll protein (PerCP) ( Table 1) . Based on immunophenotype results from diagnosis, the individual follow-up protocols were tailored (Table 1) 
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After acquisition of 15 × 10 3 events from total BM, the 'livegate' was set on the lineage-specific marker (CD19 for B precursor and cyCD3 for T cell ALL) and side scatter correspond- ing to that from diagnosis. 2 During analysis, the percentage of events with characteristics corresponding to leukemia-related immunophenotypes was evaluated. The aberrant marker expression made it possible to differentiate MRD from regenerating B cell precursors (Figure 2a ) 19 or normal T cells (Figure 2b) . 21 A cluster of at least 10 cells with leukemiarelated phenotype was considered as detectable MRD. In all but six samples a total of 1 × 10 5 -2 × 10 6 cells passed through the flow cytometer giving a sensitivity level of at least 10 −4 . In six samples the level of detection was 10 −3 .
Statistical analysis
Cohen's kappa test measuring agreement between the evaluation of two rates when both are rating the same object and SPSS statistical package were applied. 
Results
MRD evaluation by ASO-PCR
DNA samples from bone marrow taken at diagnosis from 30 ALL patients (Table 1) were analyzed using consensus primers and heteroduplex analysis for the rearrangement of the TcR␥ and TcR␦ genes. The results of the sequences of TcR␥ and TcR␦ junctional regions are given in Table 2 . In five of 30 (17%) patients (Nos 25-29) no TcR␥ and ␦ rearrangement could be found with the applied set of primers. In the 25 ALL cases, a total number of 43 clones were identified (eight TcR␦ and 35 TcR␥). For all 25 patients, at least one pair of specific primers as designed and used in the second allele-specific ASO-PCR (Table 3 ). The sensitivity of the method as assessed by serial dilutions ranged between 10 −3 and 10 −6 (Table 3, Figure 1 ). In two patients (Nos 7 and 18) all variants of designed primers showed non-specific amplification of polyclonal control DNA from PBL in all dilutions and even with limited number of cycles. Thus, a total of 23 out of 30 (77%) patients could be followed by ASO-PCR. The results of 89 follow-up samples from 23 cases successfully analyzed with ASO-PCR are given in Figure 3 and exemplified in Figure 1 . In eight patients (Nos 1, 3, 6 and 12-16), two different clones were followed. In five of these patients, only one of the clones remained detectable.
MRD evaluation by flow cytometry with 'live-gate' analysis
Based on the comparison of the immunophenotypes from diagnosis with patients of normal BM marker expression and on aberrant expression of myeloid markers it was possible to determine individual follow-up protocols for FC studies in 29 of 30 (97%) patients (Table 1) . The results were expressed as percentages of total BM cells. The results obtained in 149 follow-up bone marrow samples are presented in Figure 3 . In 723 cases where no MRD population could be identified, the sensitivity level of MRD detection (Ͻ0.1%, Ͻ0.01% or Ͻ0.001%) is given based on the number of cells analyzed by 'live-gate' approach ( Figure 3) . Figure 2 illustrates how MRD leukemic cells could be distinguished from regenerating B cell precursors 19 in a case of B precursor ALL (case No. 17, follow-up sample after the second induction treatment) or normal T cells 21 in a case of T-ALL (case No. 1, follow-up sample at the end of treatment).
Comparison of the results obtained by flow cytometry and ASO-PCR
The MRD detection results could be compared in 89 BM samples collected in complete remission (Figure 3 ). FC and ASO-PCR showed significantly consistent results (in 70 of 89 samples (78%), (kappa 0.554, P Ͻ 0.001). 33 BM samples taken during the first phase of treatment (during or immediately after induction treatment) showed a much lower level of consistency (25 of 36 samples, (69%), kappa 0.194, P Ͼ 0.05). This was mostly due to the negative results obtained in 10 FC samples, which appeared to be positive by PCR. However, in four of these 10 samples the numbers of cells that could be analyzed in 'live'-gate analysis gave the sensitivity level of 10 −3 only. By comparison, BM samples taken during later phases of treatment showed higher levels of agreement than the total material (45 of 53 samples, (85%) kappa 0.732, P Ͻ 0.001). However, also among late samples, there were some showing discordant results: five FC+/PCR− and three FC−/PCR+. The five samples where PCR results were negative and FC positive (patients 11, 12, 15 and 16, see Figure 3) were investigated for the presence of PCR inhibitors. The PCR product bands obtained from the samples where control DNA was mixed with patient DNA were weaker than the control bands run in parallel suggesting the presence of PCR inhibitors, which may explain the negative results.
MRD levels and outcome of the patients
Of 29 patients evaluated at the end of the induction treatment, 18 (62%) had detectable MRD. In 13 patients (45%) both FC and ASO-PCR results were positive. In four patients (14%) the ASO-PCR was positive, while FC did not show any detectable aberrant population. However, in two of these cases the detection limit by FC was low (Ͻ10 −3 ) due to low cellularity of the BM sample. In three patients (10%), no MRD could be detected at the end of induction treatment by either method, and in six other patients (20%) that could not be assessed by PCR the FC analysis showed Ͻ0.01% aberrant cells.
Six patients suffered relapse of disease during follow-up. In two of these patients (Nos 5 and 6), relapse occurred during treatment: 15 months and 9 months after diagnosis, respectively. All follow-up samples from these patients were positive for MRD by both methods at all time points preceding relapse. The third patient (case No. 19) was followed after the first relapse and suffered the second relapse 3 months after the end of therapy. In this patient, detectable MRD was present in all Leukemia samples taken during treatment with positivity by both FC and PCR at the end of therapy. In the fourth relapse patient (case No. 12, relapsed 44 months after diagnosis, 20 months after the end of therapy), a negative PCR result was found at the 15 month follow-up analysis but it appeared positive again at the end of treatment. Low levels of MRD were found in the same material by flow cytometry. The fifth patient (case No. 11, relapsed 40 months after diagnosis, and 16 months after the end of therapy) was positive by FC but negative by PCR after re-induction and at the end of treatment. The negative PCR results in both these patients can be explained by the presence of PCR inhibitors (see above). The sixth relapse patient (case No. 15, relapsed 46 months after diagnosis, and 22 months after the end of treatment) showed relatively high levels of MRD by FC during the whole treatment and the presence of one of the tested clones by PCR at the end of treatment. In all relapse patients, the MRD levels measured by FC increased preceding relapse.
However ). The observation time in these patients is still too short to draw definite conclusions.
Discussion
Studies where the results of prospective MRD monitoring by FC-and PCR-based molecular methods are compared in a relatively large number of follow-up BM samples from ALL patients are still very scarce. 26 Here, we have applied flow cytometry (FC) and allele specific oligonucleotide (ASO)-PCR for TcR to MRD studies in 89 follow-up samples from 23 ALL patients. Due to the over-representation of T-ALL in the available material, we have chosen to use ASO-PCR detecting TcR␥ and ␦ rearrangements rather than detection of IgH gene rearrangements. The TcR␥ and/or ␦ rearrangements have been demonstrated in virtually all T ALL and in 80% of childhood B-precursor ALL. 27 This is in agreement with the frequency obtained in our material. If both IgH and TcR targets were applied, a larger number of B-precursor ALL patients could have been followed by PCR methodology. It would also increase the number of patients who could be followed by two clonal markers. However, the main objective of the study was to compare the results obtained in the same follow-up samples, rather than to evaluate the overall prognostic significance of the two methods, which would require a much larger number of patients and a longer follow-up. Our material shows a significant level of agreement in the results obtained by FC and ASO-PCR (78% samples with con-
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Figure 3
Comparison of MRD follow-up results obtained by flow cytometry and ASO-PCR in 29 ALL cases.
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sistent results), which is in agreement with a previous study by Neale et al. 26 Results obtained in samples taken during early phases of treatment (at day 15 and day 29, ie under or immediately after the induction treatment) showed a lower level of agreement than samples taken later on during followup. In 10/11 discrepant samples from these early time points the flow cytometry showed negative results, while PCR was positive. In four of these samples the total number of cells analyzed was low giving sensitivity level of 10 −3 only. However, in five of six relapse patients the 'after induction' samples were positive by both methods. The sixth patient who relapsed had the 'after induction' sample negative by FC (at sensitivity level 10 −3 ), but subsequent follow-up samples showed the presence of MRD. In the follow-up BM samples collected during the early phases of treatment the numbers of cells available for 'live-gate' analysis were lower and levels of blood contamination higher than in samples collected during later phases of treatment (own unpublished observations). It has to be pointed out that these samples were taken under or immediately after the most intensive phase of treatment and during the early regeneration of the bone marrow. The sensitivity level in our FC MRD studies is highly dependent on the numbers of cells that pass the flow cytometer during the 'livegate' acquisition and in consequence, on the numbers of acquired CD19
+ (in cases of B ALL) or cyt.CD3 + (in T ALL) lymphoid cells. By our method, a cluster of aberrant cells that are considered as MRD must consist of at least 10 cells. To obtain the average sensitivity level of at least 10 −4 the numbers of cells that pass the flow cytometer during the 'live-gate' acquisition have to exceed 100 000 cells. This level of sensitivity was confirmed by dilution experiments performed in our laboratory (data not shown) and is similar to that observed in other studies. 2, 23 MRD detection levels obtained with our ASO primers varied in dilution experiments between 10 −3 and 10 −6 (Table 3) , which is in agreement with other studies applying similar methods 34 and other PCR-based approaches. 10, 13, 35, 36 Therefore, in practice, the MRD detection level by PCR is often one log higher than that of flow cytometry. This is illustrated by our case No. 14, where positive PCR results for one of the tested clones (with detection limit 10 −6
) and negative FC results were found at the end of treatment and 3 months later. This patient remains in continuous CR at the last followup, 70 months after diagnosis, which poses the question if MRD tests with a very high level of sensitivity (Ͼ10 −5 ) will appear to be of clinical significance. Some studies, applying highly sensitive nested PCR methods, reported a high percentage of patients who showed PCR-positive follow-up BM samples at the end of treatment and did not suffer relapse. 13 In other studies applying only slightly less sensitive methods there were patients with PCR-negative samples at the end of treatment and subsequent relapse. 6, 8, 36, 37 Some of the latter discrepancies may be explained by the disappearance of some leukemic clones, or the presence of PCR inhibitors, but in the majority of cases reported, at least one PCR target remained stable. 6 Most of the previous studies where semi-quantitative PCR methods were applied suggested that the clinically significant level of MRD would be above 1 per 10 3 BM cells. 6, 8, 9, 37 However, the reliability of all PCR-based methods depends on stringently applied rather laborious procedures. The newly developed quantitative methods (RQ-PCR) that could bring quantitative PCR to clinical practice still await clinical evaluation. 38 Few hitherto published studies on MRD using multi-parameter FC method with 'live-gate' analysis in larger cohorts of Leukemia ALL patients confirm that there is a need for quantitative evaluation of MRD. 2, 23 Moreover, in these studies the level of MRD exceeding 1/10 3 BM cells or an increase of MRD level in consecutive samples was associated with high risk of relapse. 2, 23, 39 Flow cytometric methodology is widely accessible and, if necessary, provides results within a few hours from BM sampling. Studies performed within BIOMED I Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation proved that it is possible to standardize the flow cytometric methodology between six participating laboratories from various European countries. Moreover, the thorough studies of the patterns of marker expression in normal bone marrow made it possible to detect aberrant marker expression on leukemic cells in a high number of ALL cases. 21, 40 In conclusion, our results suggest that FC with 'live-gate' analysis that is quantitative, provides quick determination of MRD levels and is far less expensive and laborious than PCRbased molecular methods, and offers an MRD detection tool that can be easily applied in clinical practice with quality comparable to molecular methods.
